OBJECTIVE: In order to examine the role of insulin-like growth factors in the pathogenesis of accelerated macrovascular disease in noninsulin-dependent diabetes mellitus (NIDDM), we investigated the relationship between the insulin resistance syndrome and the IGF axis. DESIGN: Cross-sectional analysis of the relationship between insulin resistance syndrome variables and concentrations of IGF-1, IGF-2, IGFBP-1 and IGFBP-3 in 80 subjects with NIDDM. RESULTS: After correcting for age, sex and body mass index, concentrations of IGFBP-1, correlated with those of HDL-cholesterol (r = 0.40; P < 0.001), triglycerides (r = -0.24; P = 0.04), insulin (r = -0.39; P < 0.001), intact proinsulin (r = -0.32; P = 0.006), des 31,32 proinsulin (r = -0.40; P = 0.001), and with insulin sensitivity (r = 0.38; P = 0.001) and PAI-1 activity (r = -0.24; P = 0.05); IGF-1 levels only correlated with those of HDL-cholesterol (r = -0.33; P = 0.005), and this was not explained by IGFBP-1 or insulin sensitivity. With additional correction for insulin, concentrations of IGFBP-1 still correlated with HDL-cholesterol (r = 0.40; P < 0.001), but not those of triglycerides or PAI-1 activity. There were no significant relationships between levels of IGF-2 and any of the variables investigated, and IGFBP-3 levels only correlated with those of total cholesterol (r = 0.24, P = 0.04). CONCLUSIONS: In NIDDM, concentrations of IGFBP-1 are related to those of insulin, insulin sensitivity, serum lipoproteins and PAI-1 activity. The relationship between concentrations of IGFBP-1 and HDL-cholesterol is not explained by insulin. Concentrations of IGF-1 are linked to HDL-cholesterol, and this is not explained by levels of IGFBP-1. IGFBP-1 concentrations were related to PAI-1 activity, and this may be explained by insulin, which regulates the production of IGFBP-1 and PAI-1.
OBJECTIVE: In order to examine the role of insulin-like growth factors in the pathogenesis of accelerated macrovascular disease in noninsulin-dependent diabetes mellitus (NIDDM), we investigated the relationship between the insulin resistance syndrome and the IGF axis. DESIGN: Cross-sectional analysis of the relationship between insulin resistance syndrome variables and concentrations of IGF-1, IGF-2, IGFBP-1 and IGFBP-3 in 80 subjects with NIDDM. RESULTS: After correcting for age, sex and body mass index, concentrations of IGFBP-1, correlated with those of HDL-cholesterol (r = 0.40; P < 0.001), triglycerides (r = -0.24; P = 0.04), insulin (r = -0.39; P < 0.001), intact proinsulin (r = -0.32; P = 0.006), des 31,32 proinsulin (r = -0.40; P = 0.001), and with insulin sensitivity (r = 0.38; P = 0.001) and PAI-1 activity (r = -0.24; P = 0.05); IGF-1 levels only correlated with those of HDL-cholesterol (r = -0.33; P = 0.005), and this was not explained by IGFBP-1 or insulin sensitivity. With additional correction for insulin, concentrations of IGFBP-1 still correlated with HDL-cholesterol (r = 0.40; P < 0.001), but not those of triglycerides or PAI-1 activity. There were no significant relationships between levels of IGF-2 and any of the variables investigated, and IGFBP-3 levels only correlated with those of total cholesterol (r = 0.24, P = 0.04). CONCLUSIONS: In NIDDM, concentrations of IGFBP-1 are related to those of insulin, insulin sensitivity, serum lipoproteins and PAI-1 activity. The relationship between concentrations of IGFBP-1 and HDL-cholesterol is not explained by insulin. Concentrations of IGF-1 are linked to HDL-cholesterol, and this is not explained by levels of IGFBP-1. IGFBP-1 concentrations were related to PAI-1 activity, and this may be explained by insulin, which regulates the production of IGFBP-1 and PAI-1.
Authors: A H Heald; S G Anderson; A Vyas; K Siddals; J Patel; A P Yates; D Bhatnagar; D Prabhakaran; E Hughes; A Rudenski; P Durrington; J M Gibson; J K Cruickshank Journal: Diabetologia Date: 2005-07-22 Impact factor: 10.122
Authors: Kyeezu Kim; Angela Kong; Robert C Flanigan; Marcus L Quek; Courtney M P Hollowell; Patricia P Vidal; Jefferey Branch; Leslie A Dean; Virgilia Macias; Andre A Kajadacsy-Balla; Marian L Fitzgibbon; Daisy Cintron; Li Liu; Vincent L Freeman Journal: Cancer Causes Control Date: 2019-02-07 Impact factor: 2.506
Authors: Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler Journal: Diabetes Metab Res Rev Date: 2009-01 Impact factor: 4.876
Authors: Swapnil N Rajpathak; Aileen P McGinn; Howard D Strickler; Thomas E Rohan; Michael Pollak; Anne R Cappola; Lewis Kuller; XiaoNan Xue; Anne B Newman; Elsa S Strotmeyer; Bruce M Psaty; Robert C Kaplan Journal: Growth Horm IGF Res Date: 2007-09-27 Impact factor: 2.372
Authors: Adil Rajwani; Vivienne Ezzat; Jessica Smith; Nadira Y Yuldasheva; Edward R Duncan; Matthew Gage; Richard M Cubbon; Matthew B Kahn; Helen Imrie; Afroze Abbas; Hema Viswambharan; Amir Aziz; Piruthivi Sukumar; Antonio Vidal-Puig; Jaswinder K Sethi; Shouhong Xuan; Ajay M Shah; Peter J Grant; Karen E Porter; Mark T Kearney; Stephen B Wheatcroft Journal: Diabetes Date: 2012-02-22 Impact factor: 9.461
Authors: Elina M Petäjä; You Zhou; Marika Havana; Antti Hakkarainen; Nina Lundbom; Jarkko Ihalainen; Hannele Yki-Järvinen Journal: Sci Rep Date: 2016-04-19 Impact factor: 4.379